C
Celularity Inc
Period
FY 2025
Revenue
$26.55M
Net Income
$-91.72M
Total Assets
$107.33M
Equity
$-38.06M
Shares Out
28.95M
Op. Cash Flow
$-13.25M
Business
Celularity is a cellular and regenerative medicine company developing off-the-shelf allogeneic therapies derived from postpartum human placenta to address age-related degenerative diseases and conditions. The company's pipeline includes placental-derived NK cells and MLASCs (mesenchymal-like stem cells), with lead candidate cenplacel-L in clinical development for indications including Crohn's disease, multiple sclerosis, and stroke. Celularity also manufactures and markets commercial advanced biomaterial products (Biovance, Interfyl, Rebound) for soft tissue repair and wound care, operates a biobanking service for cord blood and placental tissue storage, and provides contract manufacturing and development services to third parties.
Summary from 10-K filed 2026-04-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 27 | 54 | 23 | 18 | 21 | |
| Cost of revenues | 20 | 15 | 16 | — | — | |
| Research and development | 15 | 17 | 30 | 78 | 88 | |
| Selling, general and administrative | 51 | 59 | 51 | 66 | 71 | |
| Change in fair value of contingent consideration liability | — | −193,000 | −104 | — | — | |
| Amortization of acquired intangible assets | 1 | 2 | 2 | 2 | 2 | |
| Total operating expenses | 88 | 93 | 215 | 44 | 130 | |
| Loss from operations | −61 | −38 | −192 | −26 | −109 | |
| Interest income | 262,000 | 331,000 | 320,000 | 365,000 | 332,000 | |
| Interest expense | −7 | −6 | −3 | — | −3 | |
| Change in fair value of warrant liabilities | −3 | 398,000 | 6 | 42 | 13 | |
| Change in fair value of derivative liability | 65,000 | — | — | — | — | |
| Change in fair value of debt | −2 | −492,000 | −1 | −3 | — | |
| Loss on debt extinguishment | −6 | −4 | — | — | — | |
| Amortization of licensing obligation premium | 2 | — | — | — | — | |
| Loss on issuance of convertible notes with warrants | −2 | — | — | — | — | |
| Impairment of preferred stock investment | −3 | — | 108 | — | — | |
| Compliance fees and other expense, net | −9 | −10 | — | — | — | |
| Total other expense | −30 | −20 | −4 | 40 | 9 | |
| Loss before income taxes | −92 | −58 | −196 | 14 | −100 | |
| Income tax expense (benefit) | 3,000 | — | 10,000 | 13,000 | 20,000 | |
| Net loss | −92 | −58 | −196 | 14 | −100 | |
| Deemed dividend relating to inducement of Dragasac warrants | −64,000 | — | — | — | — | |
| Paid-in kind preferred stock dividend | −20,000 | — | — | — | — | |
| Net loss attributable to common shareholders | −92 | −58 | — | — | — | |
| Net loss per share - basic | −3.59 | −2.64 | −11.02 | 1.01 | −1.49 | |
| Net loss per share - diluted | −3.59 | −2.64 | −11.02 | 0.95 | −1.49 | |
| Weighted average shares outstanding - basic | 26 | 22 | 18 | 14 | 67 | |
| Weighted average shares outstanding - diluted | 26 | 22 | 18 | 15 | 67 | |
| Change in fair value of debt due to change in credit risk | 5,000 | −5,000 | — | — | — | |
| Comprehensive loss | −92 | −58 | −196 | 14 | −100 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-07-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6 | 738,000 | 227,000 | — | 14 | |
| Accounts receivable, net of allowance of $7,647 and $6,294 as of December 31, 2025 and 2024, respectively | 5 | 14 | 10 | — | 4 | |
| Inventory | 571,000 | 5 | 6 | — | 5 | |
| Prepaid expenses and other current assets | 920,000 | 857,000 | 2 | — | 7 | |
| Total current assets | 12 | 21 | 20 | — | 34 | |
| Property and equipment, net | 56 | 62 | 68 | — | 76 | |
| Goodwill | 7 | 7 | 7 | — | 120 | |
| Intangible assets, net | 8 | 9 | 11 | — | 121 | |
| Right-of-use assets - operating | 11 | 11 | 11 | — | 13 | |
| Restricted cash | 10 | 10 | 10 | — | 15 | |
| Inventory, net of current portion | 3 | 13 | 17 | — | 23 | |
| Other long-term assets | 247,000 | 270,000 | 337,000 | — | 376,000 | |
| Total assets | 107 | 133 | 144 | — | 401 | |
| Accounts payable | 26 | 23 | 14 | — | 6 | |
| Accrued expenses and other current liabilities | 33 | 20 | 8 | — | 9 | |
| Short-term license obligation | 2 | — | — | — | — | |
| Deferred revenue | 5 | 4 | 3 | — | 2 | |
| Preferred stock redemption liability | 300,000 | — | — | — | — | |
| Derivative liability | 92,000 | — | — | — | — | |
| Total current liabilities | 81 | 54 | 67 | — | 62 | |
| Deferred revenue, net of current portion | 3 | 3 | 3 | — | 2 | |
| Noncurrent acquisition - related contingent consideration | 1 | 1 | — | — | — | |
| Noncurrent lease liabilities - operating | 27 | 27 | 26 | — | 28 | |
| Warrant liabilities | 2 | 3 | 4 | 511,000 | 4 | |
| Long-term license obligation | 32 | — | — | — | — | |
| Deferred income tax liabilities | 12,000 | 9,000 | 9,000 | — | 9,000 | |
| Other liabilities | 266,000 | 280,000 | 294,000 | — | 321,000 | |
| Total liabilities | 145 | 124 | 103 | — | 202 | |
| Commitments and contingencies (Note 15) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 1,732,084 and 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Common Stock, $0.0001 par value, 730,000,000 shares authorized; 28,837,787 and 22,546,671 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 3,000 | 2,000 | 19,000 | — | 15,000 | |
| Additional paid-in capital | 953 | 909 | 883 | — | 844 | |
| Accumulated other comprehensive loss | — | −5,000 | — | — | 9,000 | |
| Accumulated deficit | −991 | −900 | −842 | — | −645 | |
| Total stockholders(deficit) equity | −38 | 9 | 41 | — | 199 | |
| Total liabilities and stockholders(deficit) equity | 107 | 133 | 144 | — | 401 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 7 | 8 | 9 | 9 | 9 | |
| Non cash lease expense | 110,000 | 160,000 | −13,000 | −59,000 | — | |
| Gain on amortization of licensing obligation | −2 | — | — | — | — | |
| Provision for credit losses | 1 | 457,000 | 1 | 2 | 298,000 | |
| Inventory reserve for obsolescence | −102,000 | −186,000 | — | 904,000 | — | |
| Inventory impairment | 4 | 466,000 | 5 | — | — | |
| Loss on issuance of common stock to Yorkville in connection with the Side Letter | 382,000 | — | — | — | — | |
| Loss on issuance of common stock in connection with the settlement of debt | 73,000 | — | — | — | — | |
| Issuance of warrants for Strategic Advisory Agreement | 1 | — | — | — | — | |
| Issuance of common stock due to Strategic Advisory Agreement | 108,000 | — | — | — | — | |
| Issuance of warrants to preferred stockholders in consideration of forbearance agreement | 49,000 | — | — | — | — | |
| Gain on forgiveness of interest | −991,000 | — | — | — | — | |
| Share-based compensation expense | 10 | 12 | 15 | 16 | 40 | |
| Director fees paid with RSUs | 264,000 | — | — | — | — | |
| Issuance of common stock to Palantir as consideration for settlement agreement | — | 175,000 | — | — | — | |
| Issuance of common stock to Yorkville for debt extension and SEPA commitment fee | — | 317,000 | 712,000 | — | — | |
| Issuance of common stock for consulting expense | 705,000 | 158,000 | — | — | — | |
| Change in fair value of contingent stock consideration | — | −193,000 | −159,000 | 186,000 | — | |
| Non cash interest expense | 5 | 4 | — | — | — | |
| Other, net | — | 300,000 | 4 | −37,000 | 3 | |
| Accounts receivable | 8 | −4 | −7 | −4 | −2 | |
| Inventory | 10 | 6 | −865,000 | −17 | −6 | |
| Prepaid expenses and other assets | −40,000 | 905,000 | 6 | 49,000 | 3 | |
| Accounts payable | 3 | 9 | 8 | −3 | 3 | |
| Accrued expenses and other liabilities | 13 | 13 | −1 | −3 | −2 | |
| Accrued R&D software | — | −4 | −4 | — | — | |
| Lease liabilities | 350,000 | 371,000 | 275,000 | — | — | |
| Deferred income tax liabilities | 3,000 | — | — | — | — | |
| Deferred revenue | −1 | 235,000 | 2 | 425,000 | — | |
| Net cash used in operating activities | −13 | −6 | −39 | −138 | −110 | |
| Capital expenditures | — | −161,000 | −1 | −5 | −6 | |
| Rebound asset acquisition | — | −2 | — | — | — | |
| Proceeds from Sanuwave convertible note receivable | — | 2 | — | — | — | |
| Net cash provided by investing activities | — | 514,000 | −4 | −5 | −6 | |
| Transaction costs related to the issuance of promissory notes with warrants | −40,000 | — | −2 | −3 | −11 | |
| Proceeds from Issuance of promissory notes with warrants | 10 | — | — | — | — | |
| Proceeds from warrants and short-term debt - related parties | — | 15 | 18 | — | — | |
| Proceeds from issuance of short-term debt - unaffiliated | — | 4 | 2 | — | — | |
| Repayment of short-term debt - unaffiliated | — | −17 | −17 | — | — | |
| Payment of SEPA commitment fee | — | −25,000 | — | — | — | |
| Proceeds from the sale of common stock in June 2025 PIPE | 1 | — | — | — | — | |
| Proceeds from the sale of common stock and warrants in July 2025 PIPE | 2 | — | — | — | — | |
| Proceeds from related party note with KTL Warrant | 7 | — | — | — | 5 | |
| Proceeds from the exercise of stock options | 108,000 | 58,000 | 304,000 | 862,000 | 638,000 | |
| Cash proceeds from merchant cash advance | 3 | — | — | — | — | |
| Repayment of merchant cash advance | −3 | — | — | — | — | |
| Proceeds from the exercise of warrants by Dragasac | 2 | — | — | — | — | |
| Repayment of short-term debt - related party | −121,000 | −146,000 | −17 | — | — | |
| Proceeds from issuance of preferred stock with warrants in PIPE Offering | 2 | 6 | — | — | — | |
| Tax withholding on vesting of restricted stock units | −193,000 | −434,000 | −101,000 | −132,000 | — | |
| Repayment of related party notes | −6 | — | — | — | −5 | |
| Net cash provided by financing activities | 19 | 7 | 24 | 120 | 99 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 5 | 814,000 | −19 | −23 | −17 | |
| Cash paid for interest | 3 | 144,000 | 1 | — | 146,000 | |
| Cash paid for income taxes | 52,000 | — | — | — | — | |
| Residual fair value of warrants issued with promissory notes | 336,000 | — | — | — | — | |
| Reclass of redemption value of preferred shares from equity to liability | 300,000 | — | — | — | — | |
| Conversion of unsecured senior convertible note | 922,000 | — | — | — | — | |
| Conversion of Yorkville convertible note | 3 | — | — | — | — | |
| Common stock issued for short-term debt conversion | — | 2 | 5 | 4 | — | |
| Exchange of IP assets for license obligation | 36 | — | — | — | — | |
| Preferred stock received for product purchase credits | 3 | — | — | — | — | |
| Property and equipment included in accounts payable and accrued expenses | — | −87,000 | −223,000 | −683,000 | −970,000 | |
| Reclassification of RWI Bridge warrants from liability classified to equity classified | 9 | — | — | — | — | |
| Reclassification of November 2024 Purchaser and Placement Agent warrants from liability classified to equity classified | 501,000 | — | — | — | — | |
| Reclassification of KTL Warrants from liability classified to equity classified | 9 | — | — | — | — | |
| Issuance of RWI warrants and extinguishment of promise to issue warrants liability | 1 | — | — | — | — | |
| Deemed dividend relating to inducement of Dragasac warrants | 64,000 | — | — | — | — | |
| Settlement of contingent stock consideration liability | 27,000 | — | — | — | — | |
| Paid-in kind preferred stock dividends | 20,000 | — | — | — | — | |
| Modification of C.V. Starr warrants in connection with forbearance | — | 51,000 | — | — | — | |
| Issuance of RWI warrants in connection with forbearance | — | 1 | — | — | — | |
| Inventory acquired in connection with Rebound asset acquisition | — | 2 | — | — | — | |
| Reclassification of warrants from liability classified to equity classified | — | 3 | — | — | — | |
| Assumption of short-term debt - unaffiliated by related party | — | 2 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Celularity Inc's CIK number?
Celularity Inc's SEC CIK number is 0001752828 (1752828). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Celularity Inc's SEC filings?
All of Celularity Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Celularity Inc last report earnings?
Celularity Inc (CELU) most recently filed an earnings 8-K with the SEC on May 9, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001641172-25-009462). This is Celularity Inc's most recent earnings filing of record — not a forecast of its next earnings date.
What is Celularity Inc's most recent earnings 8-K?
Celularity Inc's latest earnings 8-K (Item 2.02) was filed May 9, 2025 under accession 0001641172-25-009462. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Celularity Inc's latest earnings 8-K →
Look up any company's CIK number →